Impact of estrogen therapy on Alzheimer's disease: A fork in the road?

CNS Drugs

Volumn 18, Issue 7, 2004, Pages 405-422

  Brinton, Roberta D ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; FOLLITROPIN; GESTAGEN; MEDROXYPROGESTERONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROGESTERONE; PROGESTERONE DERIVATIVE; PROTEIN BCL 2; RALOXIFENE; SEX HORMONE; TAMOXIFEN; TESTOSTERONE;

AGING; ALZHEIMER DISEASE; BRAIN; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; MINI MENTAL STATE EXAMINATION; NERVE CELL; NEUROPROTECTION; PATHOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CLINICAL TRIALS; COGNITION; DRUG EVALUATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; HUMANS; MODELS, NEUROLOGICAL; TREATMENT OUTCOME;

EID: 2942547765     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418070-00001     Document Type: Review

References (85)

1. Fillit HM, O'Connell AW, Brown WM, et al. Barriers to drug discovery and development for Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16 Suppl. 1: S1-8
2. Alzheimer's Disease Education & Referral Center. Alzheimer's disease: unraveling the mystery [online]. Available from URL: http://www.alzheimers.org/ unraveling/unraveling.pdf [Accessed 2003 Mar 9]
3. Whitehouse PJ. Alzheimer's disease: an international public health problem. Clinical goals, strategies, and outcomes. In: Decker MW, editor. Pharmacological treatment of Alzheimer's disease. New York: Wiley-Liss, 1997: 331-43
4. Birge SJ. The role of estrogen in the treatment of Alzheimer's disease. Neurology 1997; 48 (5 Suppl. 7): S36-41
5. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-42
6. Brinton RD. A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health. Int J Fertil Womens Med 1999; 44 (4): 174-85
7. Payami H, Montee K, Grimslid H, et al. Increased risk of familial late-onset Alzheimer's disease in women. Neurology 1996; 46(1): 126-9
8. Gao S, Hendrie HC, Hall KS, et al. The relationship between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998; 55 (9): 809-15
9. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002 Nov 6; 288 (17): 2123-9
10. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002; 156 (5): 445-53
11. North American Menopause Society. Menopause core curriculum study guide: basic overview, definitions, & statistics [online]. Available from URL: http://www.menopause.org [Accessed 2003 Mar 9]
12. Henderson VW. Hormone therapy and the brain: a clinical perspective on the role of estrogen. New York: Parthenon Publishing, 2000
13. Holden C. New populations of old add to poor nations' burdens. Science 1996 Jul 5; 273 (5271): 46-8
14. Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279 (9): 688-95
15. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348 (9025): 429-32
16. LeBlanc ES, Janowshy J, Chan BK, et al. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA 2001; 285 (11): 1489-99
17. Brinton RD, Yamazaki RS. Advances and challenges in the prevention and treatment of Alzheimer's disease. Pharm Res 1998; 15: 384-97
18. Gandy S, Almeida OP, Fonte J, et al. Chemical andropause and amyloid-β peptide. JAMA 2001; 285 (17): 2195-6
19. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003 May 28; 289 (20): 2651-62
20. Troncoso JC, Martin LJ, Dal FG, et al. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging 1996; 17 (3): 365-71
21. Troncoso JC, Cataldo AM, Nixon RA, et al. Neuropathology of preclinical and clinical late-onset Alzheimer's disease. Ann Neurol 1998; 43 (5): 673-6
22. LeBlanc ES, Janowsky J, Chan BK, et al. Hormone replacement therapy and cognition; systematic review and meta-analysis. JAMA 2001 Mar 21; 285 (11): 1489-99
23. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003; 289 (20): 2673-84
24. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003 Jun 25; 289 (24): 3243-53
25. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003 May 28; 289 (20): 2663-72
26. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer's disease: a critical time. JAMA 2002 Nov 6; 288 (17): 2170-2
27. Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002; 143 (1): 205-12
28. Nilsen J, Brinton RD. Impact of progestins on estradiol-potentiation of the glutamate calcium response. Neuroreport 2002; 13(6): 825-30
29. Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. PNAS 2003; (100): 10506-11
30. Yaffe K. Hormone therapy and the Brain: déjà vu all over again? JAMA 2003 May 28; (289): 2717-9
31. Shumaker SA, Reboussin BA, Espeland MA, et al. The Women's Health Initiative Memory Study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Controlled Clinical Trials 1998; (19): 604-21
32. DiazBrinton R, Chen S, Montoya M, et al. The women's health initiative estrogen replacement therapy is neurotrophic and neuroprotective. Neurobiol Aging 2000; 21 (3): 475-96
33. Neurgaren BL, Kraines RJ. Menopausal symptoms in women of various ages. Psychosomatic Med 1965; (27): 266-73
34. McEwen BS, Alves SE, Bulloch K, et al. Ovarian steroids and the brain: implications for cognition and aging. Neurology 1997; 48 (5 Suppl. 7): S8-15
35. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol 1985; 89 (2): 484-90
36. Sherwin BB. Oestrogen and cognitive function throughout the female lifespan. Novartis Foundation Symp 2000; (230): 188-96; discussion 196-201
37. Maki P, Zonderman A, Resnick S. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry 2001; 158 (2): 227-33
38. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect? Neurology 1997; 49 (6): 1491-7
39. Sherwin BB. Estrogen and cognitive aging in women. Trends Pharmacol Sci 2002; 23 (11): 527-34
40. Brinton RD. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem 2000; 8 (3): 121-33
41. Nilsen J, Chen S, Brinton RD. Dual action of estrogen on glutamate-induced calcium signaling: mechanisms requiring interaction between estrogen receptors and src/mitogen activated protein kinase pathway. Brain Res 2002; 930 (1-2): 216-34
42. Wade CB, Robinson S, Shapiro RA, et al. Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 2001; 142 (6): 2336-42
43. Singh M, Setalo Jr G, Guan X, et al. Estrogen-induced activation of the mitogen-activated protein kinase cascade in the cerebral cortex of estrogen receptor-alpha knock-out mice. J Neurosci 2000; 20 (5): 1694-700
44. Woolley CS. Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Horm Behav 1998; 34 (2): 140-8
45. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994; 14 (12): 7680-7
46. Sandstrom NJ, Williams CL. Memory retention is modulated by acute estradiol and progesterone replacement. Behav Neurosci 2001; 115(2): 384-93
47. Dubal DB, Zhu H, Yu J, et al. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. PNAS 2001; 98 (4): 1952-7
48. Yaffe K, Lui IY, Grady D, et al. Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older women. Biol Psychiatry 2002; 51 (8): 677-82
49. Klein R, Berlin L. Benefits and risks of hormone replacement therapy. In: Pavlik EJ, editor. Estrogens, progestins and their antagonists. Boston (MA): Birkhäuser, 1996: 3-50
50. Mattox JH, Shulman LP. Combined oral hormone replacement therapy formulations. Am J Obstet Gynecol 2001; 185 (2 Suppl.): S38-46
51. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000 Jan 26; 283 (4): 485-91
52. Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288 (3): 321-33
53. Newton J. The current status of intra-uterine contraceptive devices and systems. Br J Fam Plann 2000; 26 (1): 14-5
54. Davis AJ. Advances in contraception. Obstet Gynecol Clin North Am 2000 Sep; 27 (3): 597-610, vii
55. Lahteenmaki P, Jukarainen H. Novel delivery systems in contraception. Br Med Bull 2000; 56 (3): 739-48
56. Brinton RD, Chen S, Montoya M, et al. The Women's Health Initiative estrogen replacement therapy is neurotrophic and neuroprotective. Neurobiol Aging 2000; (21): 475-96
57. Green PS, Gridley KE, Simpkins JW. Nuclear estrogen receptor-independent neuroprotection by estratrienes: a novel interaction with glutathione. Neuroscience 1998; 84 (1): 7-10
58. Behl C, Skutella T, Lezoualc'h F, et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997; 51 (4): 535-41
59. Simpkins JW, Rajakumar G, Zhang YQ, et al. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg 1997; 87 (5): 724-30
60. Pike CJ. Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease. J Neurochem 1999; 72 (4): 1552-63
61. Nilsen J, Brinton RD. Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci U S A 2003 Mar 4; 100 (5): 2842-7
62. Petanceska SS, Nagy V, Frail D, et al. Ovariectomy and 17beta-estradiol modulate the levels of Alzheimer's amyloid beta-peptides in brain. Neurology 2000; 54 (12): 2212-7
63. Li R, Shen Y, Yang LB, et al. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J Neurochem 2000; 75 (4): 1447-54
64. Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998; 4 (4): 447-51
65. Callahan MJ, Lipinski WJ, Bian F, et al. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol 2001; 158 (3): 797-801
66. Zheng H, Xu H, Uljon SN, et al. Modulation of A-beta peptides by estrogen in mouse models. J Neurochem 2002; 80 (1): 191-6
67. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology 1986; 11 (3): 337-45
68. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000; 54 (2): 295-301
69. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000 Feb 23; 283 (8): 1007-15
70. Asthana S, Craft S, Baker LD, et al. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999; 24 (6): 657-77
71. Marder K, Sano M. Estrogen to treat Alzheimer's disease: too little, too late? So what's a woman to do? [letter]. Neurology 2000 Jun 13; 54 (11): 2035-7
72. Finch CE, Tanzi RE. Genetics of aging. Science 1997 Oct 17; 278 (5337): 407-11
73. Adams MM, Shah RA, Janssen WG, et al. Different modes of hippocampal plasticity in response to estrogen in young and aged female rats. Proc Natl Acad Sci U S A 2001 Jul 3; 98 (14): 8071-6
74. Hao J, Janssen WG, Tang Y, et al. Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol 2003; 465 (4): 540-50
75. Brinton RD. Selective estrogen receptor modulators (SERM) for the brain: advances and challenges in developing a NeuroSERM. Drug Dev Res 2002; 15: 1-13
76. Thibault O, Porter NM, Chen KC, et al. Calcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions. Cell Calcium 1998; 24 (5-6): 417-33
77. Solodkin A, Van Hoesen GW. Neuropathology and functional anatomy of Alzheimer's disease. In: Brioni JD, Decker MW, editors. Pharmacological treatment of Alzheimer's disease: molecular and neurobiological foundations. New York: John Wiley & Sons, 1997
78. Rebar RW. Premature ovarian failure. In: Lobo R, editor. Treatment of the postmenopausal woman: basic and clinical aspects. Philadelphia (PA): Lippincott Williams & Wilkins, 1999: 13-22
79. Hammond CB. Women's concerns with hormone replacement therapy: compliance issues. Fertil Steril 1994; 62 (6 Suppl. 2): 157S-60S
80. American Society for Reproductive Medicine. HRT use and compliance [online]. Available from URL: http://www.Asrm. org/Literature/Menopausal. Medicine/menospring01.pdf [Accessed 2004 Apr 28]
81. Grese TA, Pennington LD, Sluka JP, et al. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators. J Med Chem 1998; 41 (8): 1272-83
82. Gustafsson JA. Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 1998; 2 (4): 508-11
83. O'Neill KJ, Chen S, Brinton RD. Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Exp Neurol. In press
84. O'Neill KJ, Chen, S, Brinton RD. Impact of the selective estrogen receptor modulator, raloxifene, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 2004; 185 (1): 63-80
85. Zhao L, Chen Q, Brinton RD. Neuroprotective and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurones. Exp Biol Med (Maywood) 2002 Jul; 227 (7): 509-19